Futibatinib (TAS-120), an irreversible inhibitor of FGFR1–4, has demonstrated promising antitumor activity in various cancer cell lines harboring FGFR alterations, including BC with FGFR3 fusions [72]. The gene discussed is FGFR3; the disease is breast cancer.